- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07833176
Comparative Efficacy of Amoxicillin, Metronidazole, and Chlorhexidine in Preventing Alveolar Osteitis
Comparative Efficacy of Amoxicillin, Metronidazole, and Chlorhexidine in Preventing Alveolar Osteitis Following Lower Third Molar Extraction: A Three-Arm Double-Blinded Randomized Controlled Trial
This study will compare the effectiveness of amoxicillin, metronidazole, and chlorhexidine in preventing alveolar osteitis (dry socket) following lower third molar extraction. Participants will be randomly assigned to one of three groups: amoxicillin, metronidazole, or chlorhexidine. Participants will be assessed on Days 3 and 7 after extraction for the presence or absence of alveolar osteitis and postoperative pain. The study will determine whether there is a difference in the incidence of alveolar osteitis among the three treatment groups.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Alveolar osteitis, commonly known as dry socket, is a frequent postoperative complication following lower third molar extraction and may cause significant pain and delayed healing. This study will compare the efficacy of amoxicillin, metronidazole, and chlorhexidine in preventing alveolar osteitis following lower third molar extraction.
This is a three-arm, double-blinded randomized controlled trial to be conducted at the Department of Oral and Maxillofacial Surgery, Khyber College of Dentistry, Peshawar. Patients aged 18-40 years who require extraction of an impacted or partially erupted mandibular third molar under local anesthesia and meet the study eligibility criteria will be considered for participation.
Eligible participants who provide written informed consent will be randomly allocated to one of three groups: Group A will receive amoxicillin, Group B will receive metronidazole, and Group C will receive chlorhexidine as the control intervention. A computer-generated randomization sequence and sequentially numbered, opaque, sealed envelopes will be used for allocation concealment. Placebo tablets and placebo gel will be used to maintain blinding of participants and outcome assessors.
Following extraction, participants will receive standardized postoperative instructions according to their assigned intervention. Participants will be assessed on Days 3 and 7 following extraction. A blinded assessor will evaluate the extraction site for alveolar osteitis using Blum's criteria. The presence or absence of alveolar osteitis will be recorded as a binary outcome. Postoperative pain will also be assessed using a Visual Analogue Scale, and additional postoperative complications or adverse effects will be documented.
The primary objective is to compare the incidence of alveolar osteitis among patients receiving prophylactic amoxicillin, metronidazole, or chlorhexidine following lower third molar extraction. The overall comparison among the three groups will be performed using the Chi-square test, with Fisher's exact test used when appropriate. Planned pairwise comparisons will include amoxicillin versus chlorhexidine, metronidazole versus chlorhexidine, and amoxicillin versus metronidazole, with Bonferroni correction for multiple comparisons.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Dr Sana Mushtaq, BDS, FCPS
- Numéro de téléphone: +923349249676
- E-mail: sana.mushtaq@kcd.edu.pk
Sauvegarde des contacts de l'étude
- Nom: Dr Syed Muaz Masoom Shah, BDS, MHR
- Numéro de téléphone: +923339299120
- E-mail: muazmasoom.shah@kcd.edu.pk
Lieux d'étude
-
-
Khyber Pakhtunkhwa
-
Peshawar, Khyber Pakhtunkhwa, Pakistan, 25000
- Khyber College of Dentistry, Peshawar
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Patients aged 18 to 40 years.
- Patients requiring non-surgical extraction of impacted or partially erupted mandibular third molars under local anesthesia.
- Patients classified as American Society of Anesthesiologists (ASA) Physical Status I or II.
- Patients who provide written informed consent to participate in the study.
Exclusion Criteria:
- Known allergy or drug hypersensitivity reaction to amoxicillin or metronidazole.
- Patients presenting with active infection at the extraction site, evidenced by pus discharge.
- Periodontally compromised (Grade 1) tooth.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Amoxicillin Group
Participants will receive amoxicillin as the assigned prophylactic intervention following lower third molar extraction. Placebo gel will be provided to maintain double blinding. |
Amoxicillin will be administered as the prophylactic intervention to participants assigned to the amoxicillin group following lower third molar extraction. Placebo gel will be provided to maintain double blinding. |
|
Expérimental: Metronidazole Group
Participants will receive metronidazole as the assigned prophylactic intervention following lower third molar extraction. Placebo gel will be provided to maintain double blinding. |
Metronidazole will be administered as the prophylactic intervention to participants assigned to the metronidazole group following lower third molar extraction. Placebo gel will be provided to maintain double blinding. |
|
Comparateur actif: Chlorhexidine Control Group
Participants will receive chlorhexidine as the control intervention following lower third molar extraction. Placebo tablets will be provided to maintain double blinding. |
Chlorhexidine will be administered as the control intervention to participants assigned to the chlorhexidine group following lower third molar extraction. Placebo tablets will be provided to maintain double blinding. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Incidence of Alveolar Osteitis
Délai: Postoperative Day 3 and Day 7
|
Alveolar osteitis will be assessed as a binary outcome (yes/no) following lower third molar extraction. The incidence of alveolar osteitis will be compared among the amoxicillin, metronidazole, and chlorhexidine groups. |
Postoperative Day 3 and Day 7
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Postoperative Pain
Délai: Postoperative Day 3 and Day 7
|
Postoperative pain will be assessed using a Visual Analog Scale (VAS) with mild level (0-3), moderate level (3-7), and severe level(7-10) of pain following lower third molar extraction. Pain scores will be recorded and compared among the three study groups. |
Postoperative Day 3 and Day 7
|
|
Complications and Adverse Effects
Délai: Postoperative Day 3 and Day 7
|
Complications and adverse effects following lower third molar extraction and administration of the assigned intervention will be assessed and recorded. |
Postoperative Day 3 and Day 7
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Danish Khan, BDS*, Khyber College of dentistry
- Directeur d'études: Dr Sana Mushtaq, BDS, FCPS, Khyber College of dentistry
- Chercheur principal: Dr Syed Muaz Masoom Shah, BDS, MHR, Khyber College of dentistry
- Chercheur principal: Dr Braikhna Murad, BDS, FCPS, Khyber College of dentistry
Publications et liens utiles
Publications générales
- Arteagoitia MI, Barbier L, Santamaria J, Santamaria G, Ramos E. Efficacy of amoxicillin and amoxicillin/clavulanic acid in the prevention of infection and dry socket after third molar extraction. A systematic review and meta-analysis. Med Oral Patol Oral Cir Bucal. 2016 Jul 1;21(4):e494-504. doi: 10.4317/medoral.21139.
- Bergdahl M, Hedstrom L. Metronidazole for the prevention of dry socket after removal of partially impacted mandibular third molar: a randomised controlled trial. Br J Oral Maxillofac Surg. 2004 Dec;42(6):555-8. doi: 10.1016/j.bjoms.2004.06.015.
- Wright C, Mistry V, Smyth J, Saik WN, Innes N, Lamont T. The use of chlorhexidine in the prevention of alveolar osteitis after third molar extractions. Evid Based Dent. 2018 Mar 23;19(1):18-19. doi: 10.1038/sj.ebd.6401289.
- Babar A, Ibrahim MW, Baig NJ, Shah I, Amin E. Efficacy of intra-alveolar chlorhexidine gel in reducing frequency of alveolar osteitis in mandibular third molar surgery. J Coll Physicians Surg Pak. 2012 Feb;22(2):91-4.
- Freudenthal N, Sternudd M, Jansson L, Wannfors K. A double-blind randomized study evaluating the effect of intra-alveolar chlorhexidine gel on alveolar osteitis after removal of mandibular third molars. J Oral Maxillofac Surg. 2015 Apr;73(4):600-5. doi: 10.1016/j.joms.2014.08.035. Epub 2014 Sep 16.
- Teshome A. The efficacy of chlorhexidine gel in the prevention of alveolar osteitis after mandibular third molar extraction: a systematic review and meta-analysis. BMC Oral Health. 2017 May 19;17(1):82. doi: 10.1186/s12903-017-0376-3.
- Ramos E, Santamaria J, Santamaria G, Barbier L, Arteagoitia I. Do systemic antibiotics prevent dry socket and infection after third molar extraction? A systematic review and meta-analysis. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016 Oct;122(4):403-25. doi: 10.1016/j.oooo.2016.04.016. Epub 2016 May 11.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- La douleur
- Manifestations neurologiques
- Maladies de la bouche
- Maladies stomatognathiques
- Complications postopératoires
- Processus pathologiques
- Conditions pathologiques, signes et symptômes
- Signes et symptômes
- Douleur, Postopératoire
- Prise sèche
- Composés de soufre
- Produits chimiques organiques
- Composés hétérocycliques, 1 anneau
- Composés hétérocycliques
- Composés hétérocycliques, 2 anneaux
- Composés hétérocycliques, anneau fusionné
- Azoles
- Imidazoles
- Amides
- Biguanides
- Guanidines
- Amidines
- Pénicilline g
- bêta-lactams
- Lactame
- Nitroimidazoles
- Composés nitro
- Ampicilline
- Pénicillines
- Métronidazole
- Amoxicilline
- Chlorhexidine
Autres numéros d'identification d'étude
- KMU/DIR/CTU/2026/13
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
De-identified individual participant data underlying the results reported in the publication will be made available to qualified researchers upon reasonable request, subject to applicable ethical, institutional, and data protection requirements. The shared data may include de-identified demographic and clinical characteristics, treatment-group allocation, alveolar osteitis outcomes, postoperative pain scores, and recorded complications or adverse effects.
Délai de partage IPD
Data will become available after publication of the study results and will remain available for a period of 5 years.
Critères d'accès au partage IPD
Data will be available to qualified researchers for scientifically valid research purposes upon reasonable request. Requests will be reviewed by the study investigators and/or the relevant institutional authority. Data will be provided only after confirmation of appropriate ethical approval and compliance with applicable data protection and confidentiality requirements.
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .